AI in Clinical Trials Market Size, Share, and Trends 2024 to 2033

The global AI in clinical trials market size was estimated at USD 1.6 billion in 2023 and is expected to hit around USD 18.82 billion by 2033, poised to grow at a CAGR of 28% from 2024 to 2033. The AI in clinical trials market is driven by the urgent requirement to speed up medication development and cut expenses.

Key Takeaways

• North America held the dominating share of the AI in clinical trials market in 2023.
• By offering, the services segment held the largest market share in 2023.
• By technology, the deep learning segment held the dominating market share in 2023.
• By application, the infectious disease segment dominated the market in 2023.
• By end-user, the pharmaceutical segment held the largest share of the market in 2023; the segment is observed to sustain dominance throughout the forecast period.

AI in Clinical Trials Market Overview

Artificial Intelligence (AI) in clinical trials can revolutionize the entire drug development process. AI algorithms can quickly and cheaply sort through enormous amounts of data to find individuals who meet the requirements, cutting down on recruitment expenses and time. AI streamlines data analysis, boosting insights from large datasets and revealing hidden patterns. Artificial intelligence (AI) can evaluate past data and forecast future results, helping researchers create more successful and productive studies. AI can customize a patient's course of care according to their genetic and health characteristics. AI algorithms can swiftly identify adverse occurrences and improve patient safety by continuously analyzing medical data.

• In January 2024, A premier CRO firm, other investors, and Accenture Ventures made a strategic $2 million investment in QuantHealth, an AI-powered clinical trial design startup that mimics clinical trials. With the additional funding, the Series A round total now stands at $17 million, allowing QuantHealth to develop its platform further.

AI in Clinical Trials Market Data and Statistics

• In November 2023, AstraZeneca announced the opening of Evinova, a health technology firm whose goal is to provide patients, clinical research organizations (CROs), trial sponsors, care teams, and other stakeholders with access to digital health solutions that the pharmaceutical giant already uses on a worldwide scale. The new business would expedite clinical trial design and delivery using well-established digital technology solutions to cut costs and development time for new medications. Additionally, the company will explore digital remote patient monitoring and therapies.
• According to estimates by Goldman Sachs Research, the global pharmaceutical industry will have about $700 billion in 2023 to spend on R&D and acquisitions of other businesses. As some blockbuster treatments' patents expire, that war fund will become increasingly important.

Growth Factors

• AI-powered gadgets enable continuous monitoring of patients from a distance, enhancing real-world data collecting and decreasing the frequency of site visits which offers easy access to data.
• By automating documentation and guaranteeing conformity to industry norms and rules, artificial intelligence (AI) simplifies regulatory compliance.
• Artificial Intelligence (AI) enhances data quality and integrity by facilitating the smooth integration and administration of large and diverse datasets from multiple sources.
• AI makes it easier for enterprises and academics to collaborate by offering safe data sharing and analysis spaces. The requirement for data protection and safety brings a growth factor for AI in clinical trials market.
• AI creates patient subgroups according to clinical and genetic traits, allowing individualized treatment plans. The rising demand for tailored medicine promotes the market’s growth.

AI in Clinical Trials Market Scope

AI in Clinical Trials Market Dynamics

Drivers

Growing trend towards personalized medicine

Artificial intelligence (AI) is essential to personalized medicine because it can analyze large amounts of patient data, spot trends, and forecast each patient's unique reaction to a given medication. AI speeds up patient enrolment, simplifies data processing, and makes it easier to find patients who might be good candidates for tailored treatments in clinical trials. AI assists researchers in identifying biomarkers, stratifying patient populations, and optimizing trial design for more focused and effective results through machine learning algorithms.

AI systems can forecast how patients will react to therapies, which aids in the more effective and focused design of clinical trials. Drug development can go more quickly and economically by optimizing trial resources by recognizing potential responders and non-responders early in the process.

Artificial intelligence (AI) is used in clinical trials to speed up medication development and improve treatment precision and efficacy by customizing the regimen to each patient's needs. Clinical trial advances are fueled by the synergy between AI and personalized medicine, resulting in more individualized and potent therapeutic interventions.

Increasing recognition of AI in clinical trials by regulatory agencies

Regulatory bodies, like the food and drug administration (FDA) and other international equivalents, are becoming more aware of how artificial intelligence (AI) might improve and accelerate certain sections of clinical studies.

This recognition results from AI technologies' capacity to simplify and enhance clinical trial procedures, improving productivity, financial viability, and data accuracy. Artificial intelligence (AI) applications in clinical trials can significantly improve patient recruitment, data analysis, predictive modeling, and adverse event monitoring.

Restraint

Standardization of AI models

The development of customized AI models is necessary because of the diversity of healthcare data, which includes patient information, imaging data, and electronic health records. However, developing broadly applicable AI models in the context of clinical trials is a challenge due to the requirement for standardized protocols and frameworks.

Utilizing disparate data formats, gathering techniques, and standards by healthcare establishments can impede the smooth incorporation of artificial intelligence solutions in various contexts. Regional ethical and regulatory limitations further compound the problem of standardizing AI models for clinical trials.

Opportunities

Hyper-personalized medicine and trial design

With AI, highly customized treatment regimens may be created by analyzing massive amounts of patient data, including genetic information, lifestyle factors, and medical history. This method improves treatment efficacy by considering each person's unique response to therapy.

AI makes identifying patient groupings based on traits easier, enabling more accurate and focused clinical trial recruitment. This shortens trial schedules and increases the chance of finding significant treatment benefits in patient groups. AI-enabled hyper-personalized medicine improves patient outcomes and satisfaction. This can decrease clinical trial dropout rates, which would lessen the requirement to find new patients and increase the validity of study findings.

Democratizing clinical trial participation

By pairing qualified individuals with large datasets, artificial intelligence (AI) can assist in finding and recruiting a wider variety of participants. Doing this ensures that clinical trials represent the variety of patients in the actual world. Artificial intelligence (AI) makes it easier to incorporate real-world data into clinical trials, giving researchers a more thorough grasp of how well a treatment works in various demographics and real-world situations. AI systems can quickly examine electronic health records and other healthcare data to find possible participants. This shortens trial times and related expenses while quickening the hiring process.

Offering Insights

The services segment held the largest share of the AI in clinical trials market in 2023. Services provide customized solutions that fit into the workflows of current clinical trials. By customizing, AI applications are made to meet the unique requirements and goals of various clinical trials and healthcare institutions. When it comes to negotiating the regulatory environment around clinical trials, service providers are essential. They guarantee that AI applications abide by pertinent healthcare laws and business norms, giving stakeholders peace of mind and reducing risk.

Technology Insights

The deep learning segment held the largest share of the AI in clinical trials market in 2023. Massive amounts of complex and diverse data, including genetic data, electronic health records (EHRs), medical imaging, and other data about clinical trials, are excellent targets for deep learning processing and analysis capabilities.

More precise and effective analysis is made possible by deep learning models, especially neural networks, and the ability to extract pertinent characteristics and patterns from unprocessed data automatically. Deep learning algorithms make adaptive trial designs possible, which support real-time clinical trial data monitoring. In response to gathered data, clinical studies can be more effective and responsive by using adaptive trials to modify essential parameters, such as patient enrollment criteria or treatment regimens.

Application Insights

The infectious disease segment dominated the AI in clinical trials market in 2023, the segment is observed to continue the expansion during the forecast period. Complex data sets, such as genetic information, epidemiological data, and clinical trial outcomes, are frequently involved in infectious diseases. Large amounts of heterogeneous data may be processed and analyzed by AI effectively, enabling researchers to obtain new insights and make defensible conclusions. Artificial intelligence (AI) technology makes it possible to monitor infectious diseases in real-time, which helps in outbreak identification and response planning. This capacity is essential for successful clinical studies amid pandemics or epidemics.

End-user Insights

The pharmaceutical segment dominated the AI in clinical trials market in 2023 and the segment is expected to sustain the dominance throughout the forecast period. Pharmaceutical corporations use AI algorithms to examine large amounts of clinical data quickly. This expedites the medication development process by helping to recognize patterns, forecast patient reactions, and optimize trial methods. Artificial intelligence is employed by the pharmaceutical business to detect and alleviate possible hazards linked to clinical studies. Predictive analytics supports proactive risk management and patient safety by estimating the probability of unfavorable outcomes.

• In June 2023, to enhance the development of Anavex's medication pipeline, Partex Group's exclusive Artificial Intelligence (AI) technology will be utilized in a strategic alliance between Anavex Life Sciences and Partex Group.

Regional Insights

North America held the largest share of AI in clinical trials market in 2023. North America, especially the United States, has led in the achievements of artificial intelligence innovation and technology. Numerous top IT firms, academic organizations, and startups that concentrate on creating innovative AI solutions for various industries, including clinical trials and healthcare, can be found in the region. It has made significant financial and investment commitments to AI businesses and research projects. Private investors, government funding, and venture capital firms have demonstrated a strong desire to assist the advancement and application of AI technology in healthcare, including clinical trials.

• For instance, in August 2023, Deep 6 AI and Texas Tech University Health Sciences Center (TTUHSC) established a partnership to increase patient access to clinical trials. TTUHSC will use AI to enhance patient access to its electronic medical record (EMR) system.

Asia-Pacific is expected to witness the fastest rate of expansion in the AI in clinical trials market during the forecast period. The market is expanding due to a growing patient base, a variety of patient demographics, and comparatively lower expenses than in Western nations. As a result, there is a greater need than ever for cutting-edge technologies, such as artificial intelligence (AI), for managing and carrying out clinical studies. Asia-Pacific's large and diversified patient populations offer a wealth of data for clinical trials. Artificial intelligence (AI) technologies can enhance the efficiency of data analysis, particularly in patient recruitment, stratification, and trial lifecycle monitoring.

Recent Developments

• In September 2023, a global pioneer in providing individuals and institutions with reliable intelligence to change the world, Clarivate Plc announced the creation of an Academia & Government Innovation Incubator. This will quicken its approach to fostering creativity, using AI, and launching cutting-edge products for its academic clients and users.
• In July 2023, by advancing the first medication identified and created by generative AI into Phase II clinical trials involving humans, Insilico Medicine has set a new standard in artificial intelligence drug research. The primary program, INS018_055, is a pan-fibrotic inhibitor that may be the first of its kind. Insilico's moonshot medication unequivocally proves the viability of the company's end-to-end AI drug development platform, Pharma. AI.

AI in Clinical Trials Market Companies

• AiCure
• Antidote Technologies
• Deep 6 AI
• Mendel.ai
• Phesi
• Saama Technologies
• Signant Health
• Trials.ai
• Innoplexus
• IQVIA
• Median Technologies
• Medidata

Segments Covered in the Report

By Offering

• Software
• Services

By Technology

• Machine learning
• Deep learning
• Supervised

By Application

• Cardiovascular
• Metabolic
• Oncology
• Infectious diseases

By End-user

• Pharma
• Biotech
• CROs

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa